Thromboprophylaxis in COVID-19 - Rationale and considerations

Area of Science:

• Internal Medicine
• Hematology
• Infectious Diseases

Background:

• The COVID-19 pandemic is linked to a significant increase in thrombotic events.
• Immunothrombosis is a proposed mechanism contributing to this heightened clotting risk.
• Early recognition of thrombosis in COVID-19 spurred extensive research into anticoagulation therapies.

Purpose of the Study:

• To review the scientific rationale for thromboprophylaxis in COVID-19 patients.
• To discuss anticoagulation dosing strategies and decision-making processes.
• To explore thrombosis prevention in specific patient groups, including outpatients, pregnant women, children, individuals with obesity, and those on ECMO.

Main Methods:

• Literature review of studies on COVID-19 and thrombosis.
• Analysis of pathophysiological mechanisms, particularly immunothrombosis.
• Examination of clinical trial data and expert guidelines on anticoagulation.

Main Results:

• Anticoagulation is frequently considered for hospitalized COVID-19 patients to mitigate thrombotic risk.
• Dosing strategies vary, with some evidence supporting prophylactic or therapeutic doses depending on patient risk stratification.
• Special populations require tailored approaches to thrombosis prevention.

Conclusions:

• Thromboprophylaxis is a critical consideration in managing COVID-19 patients due to elevated thrombotic risk.
• Personalized risk assessment and appropriate anticoagulation dosing are essential.
• Further research is needed to optimize thrombosis prevention strategies across diverse patient populations affected by COVID-19.